Fig. 6: Analysis of different olaparib and carboplatin schedules in gBRCAm SUM149PT cells. | Nature Communications

Fig. 6: Analysis of different olaparib and carboplatin schedules in gBRCAm SUM149PT cells.

From: Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial

Fig. 6

A Schematic of single-agent and combination schedules of olaparib and carboplatin in TNBC gBRCAm SUM149PT cells. Squares represent treatment days with purple for olaparib and green, carboplatin treatment. B Cell cycle distribution analysis of SUM149PT. Day 4 (D4) analysis following olaparib (1 µM) and/or carboplatin (10 µM) treatment (mean values ± SD from three independent biological replicates). C DNA damage assessment at D4 of SUM149PT cells using γH2AX. Following olaparib (1 μM) and/or carboplatin (10 μM) treatment, γH2AX foci were visualised by immunofluorescence staining (mean values ± SD from three independent biological replicates, a.u. arbitrary units). D Cell viability of SUM149PT cells at day six after olaparib (0.3 μM) or carboplatin (1 μM) single agent treatments, concurrent combination or carboplatin first or olaparib first combination schedules. Viability was assessed using a cell titre glow assay (see methods). Shown are the % viability for each treatment (mean values ± SD, from three independent biological replicates). Also provided are the p-values from one-way ANOVA multiple comparisons. Source data is provided as a Source Data file.

Back to article page